News Releases

-Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis to be Presented-

--Company Supports Investigator-Initiated Study of Brensocatib (Formerly INS1007) in Severe COVID-19 and Continues to Advance Development in Bronchiectasis--

--Insmed to support STOP-COVID19 Study, Expected to Begin in the UK in May 2020--

-- Company Submits New Drug Application in Japan for ARIKAYCE® (amikacin liposome inhalation suspension) for the Treatment of Patients with NTM Lung Disease Caused by MAC --

-- Management of common adverse events through physician-guided measures resulted in symptomatic improvement --

--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $45.7 Million for the Fourth Quarter 2019 and $136.5 Million for the Full Year 2019--

-- Study Achieves Primary Endpoint with Statistically Significant Improvement in Time to First Exacerbation for Both Dosage Strengths of INS1007 Versus Placebo --

-Drayton Wise named Senior Vice President, Head of U.S.

--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $38.9 Million for the Third Quarter of 2019--

--ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $29.0 Million for the Second Quarter of 2019--

--ARIKAYCE Plus Guideline-Based Therapy (GBT) Associated with Significantly Higher Rates of Sustained Culture Conversion on Therapy and Durable Culture Conversion Three Months Post-Treatment Compared with GBT Alone--

-- ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 --

--Patent is 10th Issued in the U.S. for ARIKAYCE and Second Extending Patent Protection into 2035--

--ARIKAYCE Preliminary U.S. Net Product Sales Approximately $21.0 Million for the First Quarter of 2019--

--Sustainability and Durability Data from Phase 3 CONVERT Study of ARIKAYCE to be Presented in Late-Breaking Oral Session--